<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The platelet <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa receptor (GPIIb/IIIa, fibrinogen receptor) represents the final common pathway for platelet aggregation </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of GPIIb/IIIa with antibodies or <z:chebi fb="7" ids="16670">peptides</z:chebi> containing the RGD sequence has been reported to prevent <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined DMP 728 [(cyclic[D-2-amino-<z:chebi fb="0" ids="22972">butyryl</z:chebi><z:chebi fb="31" ids="30226">-N2</z:chebi>-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="0" ids="29952,32684">L-arginyl</z:chebi>-glycyl-<z:chebi fb="0" ids="29958">L-aspartyl</z:chebi>-3-(a min o- <z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="0" ids="30746">benzoic acid</z:chebi>], <z:chebi fb="0" ids="27376">methanesulfonic acid</z:chebi> salt], a cyclic peptidomimetic, GPIIb/IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, for prevention of <z:mp ids='MP_0005048'>thrombosis</z:mp> and rethrombosis in a canine model of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Dogs were anesthetized, and both carotid arteries were instrumented with an electrode, a flow probe, and a stenosis </plain></SENT>
<SENT sid="4" pm="."><plain>A 300-microA current was applied to the intimal surface in the right carotid artery (RCA, control) through the electrode; time to occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass was noted </plain></SENT>
<SENT sid="5" pm="."><plain>The RCA served as the control vessel; the left carotid artery (LCA) served as the test vessel after DMP 728 administration (0.1 or 1. mg/kg, intravenously, i.v.) </plain></SENT>
<SENT sid="6" pm="."><plain>As compared with controls, occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was reduced by both doses of DMP 728 (control 100% n = 12; 0.1 mg/kg i.v </plain></SENT>
<SENT sid="7" pm="."><plain>17%, p &lt; 0.05, n = 6; 1.0 mg/kg i.v </plain></SENT>
<SENT sid="8" pm="."><plain>0%, p &lt; 0.05, n = 6), time to occlusion was increased (p &lt; 0.05), and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight was reduced (p &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Ex vivo platelet aggregation was inhibited in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="10" pm="."><plain>In a second group of animals, a carotid artery <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was formed and lysed with anisoylated plasminogen activator complex (APSAC; 0.05 U/kg intraarterially, i.a.) with or without DMP 728.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>